,NR 565 Midterm Exam | Advanced Pharmacology
Fundamentals (2026) Actual Q&A PDF | Chamberlain
1. Which pharmacokinetic parameter represents the fraction of an administered drug
dose that reaches systemic circulation unchanged?
A) Volume of distribution
B) Clearance
C) Bioavailability
D) Elimination half-life
Correct Answer: Bioavailability
Rationale: Bioavailability (F) is the fraction of an administered dose that reaches
systemic circulation in an unchanged form. It is 100% for intravenous administration and
less than 100% for oral routes due to incomplete absorption and first-pass metabolism.
Volume of distribution reflects the apparent space available for drug distribution,
clearance describes the rate of drug elimination, and half-life is the time required for
plasma concentration to decrease by 50%.
2. A medication is a weak base with a pKa of 8.4. In which body compartment is this
drug most highly ionized?
A) Small intestine (pH 7.4)
B) Stomach (pH 1.5–3.5)
C) Blood (pH 7.35–7.45)
,D) Urine (pH 5.0–8.0)
Correct Answer: Stomach (pH 1.5–3.5)
Rationale: Weak bases are more ionized in acidic environments because low pH
favors protonation. The stomach's highly acidic pH causes a weak base with a pKa of 8.4
to become highly ionized. Ionized drugs are poorly absorbed across lipid membranes.
Weak bases are better absorbed in the more alkaline small intestine.
3. Which pharmacokinetic process is most directly affected by first-pass metabolism?
A) Distribution
B) Metabolism
C) Oral absorption
D) Renal excretion
Correct Answer: Oral absorption
Rationale: First-pass metabolism occurs in the liver and gut wall after oral
administration, reducing the amount of active drug reaching systemic circulation. This
process directly affects oral bioavailability. Drugs with extensive first-pass metabolism
(e.g., nitroglycerin) are often given via sublingual or intravenous routes to bypass
hepatic portal circulation.
4. A patient with hypoalbuminemia is prescribed a highly protein-bound medication.
The NP should anticipate which effect?
, A) Decreased free drug concentration
B) Increased free drug concentration with potential toxicity
C) No change in drug activity
D) Decreased drug clearance
Correct Answer: Increased free drug concentration with potential toxicity
Rationale: Hypoalbuminemia reduces protein binding sites, resulting in a higher
fraction of free (active) drug in circulation. This can lead to increased drug effect and
toxicity at standard doses. Drugs that are highly protein-bound (e.g., warfarin,
phenytoin) are particularly affected.
5. Which phase of drug development focuses on determining safety, dosing, and
adverse effects in a small group of healthy volunteers?
A) Preclinical stage
B) Phase 1 clinical trials
C) Phase 2 clinical trials
D) Phase 3 clinical trials
Correct Answer: Phase 1 clinical trials
Rationale: Phase 1 trials involve a small number (20–100) of healthy volunteers to
determine safety, dosing, and adverse effects. Preclinical testing occurs in animals and
cell cultures before human trials. Phase 2 trials evaluate efficacy in patients with the
Fundamentals (2026) Actual Q&A PDF | Chamberlain
1. Which pharmacokinetic parameter represents the fraction of an administered drug
dose that reaches systemic circulation unchanged?
A) Volume of distribution
B) Clearance
C) Bioavailability
D) Elimination half-life
Correct Answer: Bioavailability
Rationale: Bioavailability (F) is the fraction of an administered dose that reaches
systemic circulation in an unchanged form. It is 100% for intravenous administration and
less than 100% for oral routes due to incomplete absorption and first-pass metabolism.
Volume of distribution reflects the apparent space available for drug distribution,
clearance describes the rate of drug elimination, and half-life is the time required for
plasma concentration to decrease by 50%.
2. A medication is a weak base with a pKa of 8.4. In which body compartment is this
drug most highly ionized?
A) Small intestine (pH 7.4)
B) Stomach (pH 1.5–3.5)
C) Blood (pH 7.35–7.45)
,D) Urine (pH 5.0–8.0)
Correct Answer: Stomach (pH 1.5–3.5)
Rationale: Weak bases are more ionized in acidic environments because low pH
favors protonation. The stomach's highly acidic pH causes a weak base with a pKa of 8.4
to become highly ionized. Ionized drugs are poorly absorbed across lipid membranes.
Weak bases are better absorbed in the more alkaline small intestine.
3. Which pharmacokinetic process is most directly affected by first-pass metabolism?
A) Distribution
B) Metabolism
C) Oral absorption
D) Renal excretion
Correct Answer: Oral absorption
Rationale: First-pass metabolism occurs in the liver and gut wall after oral
administration, reducing the amount of active drug reaching systemic circulation. This
process directly affects oral bioavailability. Drugs with extensive first-pass metabolism
(e.g., nitroglycerin) are often given via sublingual or intravenous routes to bypass
hepatic portal circulation.
4. A patient with hypoalbuminemia is prescribed a highly protein-bound medication.
The NP should anticipate which effect?
, A) Decreased free drug concentration
B) Increased free drug concentration with potential toxicity
C) No change in drug activity
D) Decreased drug clearance
Correct Answer: Increased free drug concentration with potential toxicity
Rationale: Hypoalbuminemia reduces protein binding sites, resulting in a higher
fraction of free (active) drug in circulation. This can lead to increased drug effect and
toxicity at standard doses. Drugs that are highly protein-bound (e.g., warfarin,
phenytoin) are particularly affected.
5. Which phase of drug development focuses on determining safety, dosing, and
adverse effects in a small group of healthy volunteers?
A) Preclinical stage
B) Phase 1 clinical trials
C) Phase 2 clinical trials
D) Phase 3 clinical trials
Correct Answer: Phase 1 clinical trials
Rationale: Phase 1 trials involve a small number (20–100) of healthy volunteers to
determine safety, dosing, and adverse effects. Preclinical testing occurs in animals and
cell cultures before human trials. Phase 2 trials evaluate efficacy in patients with the
